Key result
SP16 enters a planned trial versus placebo to prevent AKI after cardiac surgery.
Why the study?
Acute kidney injury is a frequent organ failure after cardiac surgery using cardiopulmonary bypass, especially in chronic kidney disease patients, and no approved drug treatments effectively prevent it.
Does SP16 prevent acute kidney injury and is it safe in patients with chronic kidney disease undergoing elective cardiac surgery?
RCT (n=120)
Double-blind
1:1
No
Does SP16 prevent acute kidney injury and is it safe in patients with chronic kidney disease undergoing elective cardiac surgery?
This phase IIa trial protocol outlines a study to evaluate the safety and efficacy of the LRP1 agonist SP16 in preventing cardiac surgery-associated acute kidney injury in patients with pre-existing chronic kidney disease.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“AKI after cardiac surgery remains a major unmet medical need with no approved pharmacologic therapy. Receiving unconditional approval to initiate the EASE AKI trial underscores the strength of our clinical package and the promise of SP16 as a novel, inflammation resolving therapeutic capable of protecting vulnerable patients during high risk procedures.”
“SP16, as a novel, possesses the potential to resolve inflammation and serve as a therapeutic agent capable of safeguarding vulnerable patients during high-risk medical procedures.”
“we are excited to bring a much-needed treatment options to minimize the risk for acute kidney injury to subjects with CKD undergoing elective cardiac surgery”
SP16 may offer first pharmacologic AKI prevention in high-risk cardiac surgery; RCT extends preclinical signals but requires confirmation before practice change.
BACKGROUND: Cardiac surgery using cardiopulmonary bypass uses controlled hypoperfusion which leads to relative organ damage. Acute kidney injury is the most frequent and most important organ failure, in particular in patients with chronic kidney disease. To date, there are no approved drug treatments that could effectively prevent acute kidney injury. SP16, an agonist of the low-density lipoprotein receptor-related protein 1, has been shown to exert both kidney- and cardioprotective effects in preclinical trials. Early clinical use of SP16 in phase I trials was safe. Administration of SP16 had beneficial trends on inflammatory response and infarct size in patients with ST-segment elevation myocardial infarction. The primary objective of this phase IIa trial is to demonstrate that injection of SP16 is safe and superior to placebo in preventing cardiac surgery-associated acute kidney injury within 7 days after surgery. METHODS: This randomised, double-blinded, placebo-controlled, single-centre study evaluates the efficacy and safety of SP16 in 120 high-risk chronic kidney disease patients with disease stage G2-G3b undergoing cardiac surgery who are randomised into one of two treatment groups in a 1:1 ratio: SP16 (12 mg) or placebo. The study medication is administered via two subcutaneous injections, with the first dose given before surgery, followed by an additional dose after 9 h. Primary endpoints are the incidence of acute kidney injury during 7 days post-surgery and the frequency of adverse events within 72 h after index surgery. Important secondary endpoints include the incidence of major adverse kidney events at day 90 and impact on cardiac function. Safety assessments encompass adverse events, vital signs, electrocardiograms and routine safety laboratory tests. Additional evaluations include pharmacokinetics and immunological biomarkers. DISCUSSION: This single-centre phase IIa trial will assess the incidence of cardiac surgery-associated acute kidney injury, describing the kidney-protective potential of SP16 and its safety profile in patients undergoing cardiac surgery. TRIAL REGISTRATION: EUCT, EUCT number 2025-522491-89-00. Registered on February 2, 2026, https://euclinicaltrials.eu/ctis-public/view/2025-522491-89-00 . Patient recruitment is planned to start on August 1, 2026.
No takes yet. Share an insight, caveat, or question.
Jobst‐Schwan et al. (2026) conducted an RCT in Chronic kidney disease undergoing elective cardiac surgery (n=120). SP16 vs. Placebo was evaluated on Incidence of acute kidney injury (KDIGO stage ≥1) within 7 days post-surgery and frequency of adverse events within 72 hours. SP16 will be evaluated for its efficacy and safety in preventing acute kidney injury compared to placebo in a planned phase IIa trial of 120 patients with chronic kidney disease undergoing cardiac surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: